– Replacing the ML‑DS 2006 reduced‑intensity induction with CPX‑351 (liposomal cytarabine:daunorubicin/cytarabine formulation) in the ML‑DS 2018 trial produced a significantly lower 24‑month event‑free survival (EFS) — 69% versus 90% (P <.001) — leading to early trial suspension.
– Despite higher relapse frequency, most relapsed patients achieved remission with salvage therapy and overall survival (OS) at 24 months remained similar to historical controls (88% vs 92%, P = .612).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
